Exhibit 23.1
Independent Registered Public Accounting Firm’s Consent
We consent to the incorporation by reference in this Registration Statement of ZyVersa Therapeutics, Inc. on Form S-8 of our report dated March 25, 2024 (except for the effects of the reverse stock split discussed in Note 11, as to which the date is July 11, 2024), which includes an explanatory paragraph as to ZyVersa Therapeutics, Inc. ability to continue as a going concern, with respect to our audits of the consolidated financial statements of ZyVersa Therapeutics, Inc as of December 31, 2023 and for the year ended December 31, 2023 appearing in the Annual Report included in the Post-effective Amendment No.1 to Form S-1 (No. 333-275320).
/s/ Marcum llp
Marcum LLP
New York, NY
January 24, 2025
